FDA-approved continuous glucose monitoring system
June 2018—Medtronic received FDA approval for its Guardian Connect continuous glucose monitoring system for people with diabetes ages 14 to 75 years.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
BD launches ccfDNA blood collection tube in Europe
June 2018—Becton Dickinson announced the commercial availability of the CE-IVD-marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland.
IgG subclass antibodies
June 2018—Binding Site’s Immunologicals Group announced the availability of affinity-purified, unconjugated, anti-human antibodies to the IgG subclasses, including IgG1, IgG2, IgG3, and IgG4, for IVD research use in solid phase enzyme immunoassay based test methods, especially ELISAs, and other potential testing applications.
Genoptix completes Rosetta acquisition
June 2018—Rosetta Genomics’ stockholders have approved the acquisition of the company by Genoptix, which will immediately begin marketing, selling, and distributing Rosetta Genomics’ products.
POC immunoassay testing system
June 2018—Sekisui Diagnostics has partnered with Qualigen to distribute the FastPack IP System, Qualigen’s POC immunoassay testing system.
AdvantEdge acquires PMI, 5/18
May 2018—AdvantEdge Healthcare Solutions, a medical billing company, has acquired Professional Management, Inc., a Baltimore-based medical billing company that provides billing services to pathology, radiology, and emergency medicine physician groups.
CMS extends coverage of Oncomine Dx test, 5/18
May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests.
ArcherDx, Ambry Genetics partnership, 5/18
May 2018—ArcherDx and Ambry Genetics announced a partnership in which Ambry will provide biopharma sequencing services using ArcherDx’s next-generation sequencing assays. Ambry Genetics will utilize Archer Immunoverse and VariantPlex NGS assays to provide large-scale immune repertoire analysis and chimeric antigen receptor T-cell manufacturing characterization and pharmacodynamics to biopharma customers.
Liquid biopsy for differential diagnosis of early stage lung cancer, 5/18
May 2018—Integrated Diagnostics announced the e-publication of full results of a large prospective clinical trial validating its Xpresys Lung 2 in Chest, titled “Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (PulmonAry NOdule Plasma proTeomIc Classifier) trial”.
sFLC assays for multiple myeloma testing, 5/18
May 2018—Sebia launched two CE-marked serum free light chain assays, Sebia FLC Kappa and Sebia FLC Lambda, for multiple myeloma testing. The two assays aim to provide more consistent results by overcoming the challenges in analytical performance and coherence encountered in current testing methods.